Navigation Links
GenWay Biotech extends the You Test You program overseas
Date:3/18/2010

(San Diego, CA) March 18, 2010 GenWay Biotech, Inc., (www.genwaybio.com) the US-based diagnostic company that recently launched the You Test YouTM Cancer Assessment is expanding this cancer testing program internationally. An agreement has been executed to offer the You Test YouTM Cancer Assessment in Greece starting in April. Additional agreements are in progress for other European nations as well. GenWay currently offers this test in the United States and Canada.

Dr. Sergey Sikora, Vice President of Business Development, said, "The agreement with Greece is one of many on the horizon which will make the You Test You cancer testing service readily available to many countries worldwide that are interested in revolutionizing healthcare and facilitating self-testing for cancer."

The You Test YouTM Cancer Assessment is a unique program that enables consumers to directly access a cancer testing service without having to make an appointment with their own doctor. The You Test You platform is designed to empower consumers to be proactive about their health and their risk of having cancer. The test measures biomarkers associated with numerous types of cancer and aids in the early detection of cancer.

Early detection of cancer is the key to fighting cancer successfully. Extending this program to other countries could bring them to a higher level of healthcare with individuals being able to self-monitor themselves for diseases such as cancer.


'/>"/>

Contact: Jill Dombrauckas, PhD
jdom@genwaybio.com
858-458-0866 x119
GenWay Biotech
Source:Eurekalert

Page: 1

Related biology news :

1. GenWay Biotechs You Test You puts early cancer detection tool in the hands of consumers
2. GenWay Clinical Laboratory receives accreditation from College of American Pathologists
3. General tumor marker test now offered by GenWay clinical laboratory
4. GenWay Biotech obtains exclusive rights to AMDLs DR-70 cancer test in US and Canada
5. New biotech advance to add heart healthy omega-3s to US diet
6. McGill, Quebec biotech firm partner for new bone-disease treatment
7. New edition of ASM Press biotechnology text announced
8. Biotech, nanotech and synthetic biology roles in future food supply explored
9. Tarantula venom-based MD therapy to be advanced by UB scientists biotech company
10. DoseCue(TM) Presents Positive Study Results at BioTech 2009
11. PDC Biotech GmbH Announces Close of Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology: